Viewing data from:

FROVATRIPTAN SUCCINATE

ANDA

FROVATRIPTAN SUCCINATE | A202931 | PHARMOBEDIENT CONSULTING LLC

1 strength0 unique patents0 unique exclusivities

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Endo Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc. et al 1:2011cv00717 3 patentsANDA 202931frovatriptan	D. Del.	2011-08-16	Terminated 2014-06-20	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Medicare Part D Spending

CMS annual spending data for Frovatriptan Succinate (2023)

Total Spending

$3.3M

Total Claims

7,853

Beneficiaries

1,913

Avg Cost/Unit

$28.96

Spending Trend

$3.6M(2019)→$3.8M(2020)→$3.6M(2021)→$3.5M(2022)→$3.3M(2023)

YoY Change:-7.0%

5yr CAGR:-2.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain3 active DMFs

3 active API suppliers hold Drug Master Files for this ingredient.

ALIVUS LIFE SCIENCES LTDFROVATRIPTAN SUCCINATE MONOHYDRATE

DMF 229522009

MATRIX PHARMACORP PRIVATE LTDFROVATRIPTAN SUCCINATE MONOHYDRATE

DMF 243112010

BIOPHORE INDIA PHARMACEUTICALS PVT LTDFROVATRIPTAN SUCCINATE MONOHYDRATE

DMF 272842013

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 2.5MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Aug 28, 2014

No patent or exclusivity listings for this strength.